Published in Mech Ageing Dev on September 01, 1985
Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol (1991) 49.03
Ubiquitin is detected in neurofibrillary tangles and senile plaque neurites of Alzheimer disease brains. Proc Natl Acad Sci U S A (1987) 2.97
The prevalence of amyloid (A4) protein deposits within the cerebral and cerebellar cortex in Down's syndrome and Alzheimer's disease. Acta Neuropathol (1990) 2.23
Alzheimer's disease: areal and laminar pathology in the occipital isocortex. Acta Neuropathol (1989) 2.09
Neurofibrillary changes confined to the entorhinal region and an abundance of cortical amyloid in cases of presenile and senile dementia. Acta Neuropathol (1990) 2.05
Ultrastructural localization of beta-amyloid, tau, and ubiquitin epitopes in extracellular neurofibrillary tangles. Proc Natl Acad Sci U S A (1991) 1.26
In vivo characterization of the early states of the amyloid-beta network. Brain (2013) 0.99
Altered pupillary size and darkness and light reflexes in Alzheimer's disease. J Neurol Neurosurg Psychiatry (1997) 0.85
The identification of pathological subtypes of Alzheimer's disease using cluster analysis. Acta Neuropathol (1994) 0.81
Genetic analysis of Down syndrome facilitated by mouse chromosome engineering. Bioeng Bugs (2012) 0.80
Subcortical afferent projection systems in Huntington's chorea. Acta Neuropathol (1989) 0.78
Oxidative Stress in Alzheimer's Disease: Should We Keep Trying Antioxidant Therapies? Cell Mol Neurobiol (2015) 0.77
Neuron-astrocyte interactions in neurodegenerative diseases: Role of neuroinflammation. Clin Exp Neuroimmunol (2015) 0.76
Negative regulation of transforming growth factor-beta by the proteoglycan decorin. Nature (1990) 4.90
Amyloid beta protein (A beta) deposition: A beta 42(43) precedes A beta 40 in Down syndrome. Ann Neurol (1995) 3.34
Frontal lobe dementia and motor neuron disease. J Neurol Neurosurg Psychiatry (1990) 2.91
Dominant and differential deposition of distinct beta-amyloid peptide species, A beta N3(pE), in senile plaques. Neuron (1995) 2.90
Presence of soluble amyloid beta-peptide precedes amyloid plaque formation in Down's syndrome. Nat Med (1996) 2.71
The neural cell adhesion molecule (NCAM) as a regulator of cell-cell interactions. Science (1988) 2.49
A quantitative morphometric analysis of the neuronal and synaptic content of the frontal and temporal cortex in patients with Alzheimer's disease. J Neurol Sci (1987) 2.43
Effects of modifications of the RGD sequence and its context on recognition by the fibronectin receptor. J Biol Chem (1989) 2.00
A prospective, population-based study of the demographics, epidemiology, management, and outcome of out-of-hospital pediatric cardiopulmonary arrest. Ann Emerg Med (1999) 1.96
Lewy bodies contain altered alpha-synuclein in brains of many familial Alzheimer's disease patients with mutations in presenilin and amyloid precursor protein genes. Am J Pathol (1998) 1.93
Neuropsychological syndromes in presenile dementia due to cerebral atrophy. J Neurol Neurosurg Psychiatry (1986) 1.83
Progressive language disorder due to lobar atrophy. Ann Neurol (1992) 1.82
Apolipoprotein E4 and Alzheimer's disease pathology in Lewy body disease and in other beta-amyloid-forming diseases. Lancet (1994) 1.78
Changes in the monoamine containing neurones of the human CNS in senile dementia. Br J Psychiatry (1980) 1.74
Decorin suppresses tumor cell growth by activating the epidermal growth factor receptor. J Clin Invest (1998) 1.70
Age-related amyloid beta deposition in transgenic mice overexpressing both Alzheimer mutant presenilin 1 and amyloid beta precursor protein Swedish mutant is not associated with global neuronal loss. Am J Pathol (2000) 1.66
Disease-specific patterns of locus coeruleus cell loss. Ann Neurol (1992) 1.64
Tau, ubiquitin, and alpha B-crystallin immunohistochemistry define the principal causes of degenerative frontotemporal dementia. Arch Neurol (1995) 1.59
Identification of a 38-kDa heparin-binding glycoprotein (gp38k) in differentiating vascular smooth muscle cells as a member of a group of proteins associated with tissue remodeling. J Biol Chem (1995) 1.56
Evaluation of the NINCDS-ADRDA criteria in the differentiation of Alzheimer's disease and frontotemporal dementia. J Neurol Neurosurg Psychiatry (1999) 1.55
Alzheimer's presenile dementia, senile dementia of Alzheimer type and Down's syndrome in middle age form an age related continuum of pathological changes. Neuropathol Appl Neurobiol (1984) 1.47
Percutaneous pulmonary endoarterial biopsy in an experimental model of pulmonary hypertension. Chest (1998) 1.46
Ectopic expression of decorin protein core causes a generalized growth suppression in neoplastic cells of various histogenetic origin and requires endogenous p21, an inhibitor of cyclin-dependent kinases. J Clin Invest (1997) 1.44
Polyploidy in the human nervous system. 1. The DNA content of neurones and glia of the cerebellum. J Neurol Sci (1973) 1.41
Lipoprotein pigments--their relationship to ageing in the human nervous system. II. The melanin content of pigmented nerve cells. Brain (1974) 1.37
Full-length amyloid-beta (1-42(43)) and amino-terminally modified and truncated amyloid-beta 42(43) deposit in diffuse plaques. Am J Pathol (1996) 1.36
Alzheimer's disease: a correlative study. J Neurol Neurosurg Psychiatry (1986) 1.36
The apolipoprotein E epsilon2 allele and the pathological features in cerebral amyloid angiopathy-related hemorrhage. J Neuropathol Exp Neurol (1999) 1.31
The clinical pathological correlates of lobar atrophy. Dementia (1993) 1.31
Polyploidy in the human nervous system. 2. Studies of the glial cell populations of the Purkinje cell layer of the human cerebellum. J Neurol Sci (1973) 1.31
Some morphometric observations on the cerebral cortex and hippocampus in presenile Alzheimer's disease, senile dementia of Alzheimer type and Down's syndrome in middle age. J Neurol Sci (1985) 1.31
Huntington's disease intranuclear inclusions contain truncated, ubiquitinated huntingtin protein. Exp Neurol (1999) 1.30
Correlation between senile plaque and neurofibrillary tangle counts in cerebral cortex and neuronal counts in cortex and subcortical structures in Alzheimer's disease. Neurosci Lett (1985) 1.22
The pathology of the human locus ceruleus. Clin Neuropathol (1983) 1.20
Classification and description of frontotemporal dementias. Ann N Y Acad Sci (2000) 1.19
Lipoprotein pigments--their relationship to ageing in the human nervous system. I. The lipofuscin content of nerve cells. Brain (1974) 1.19
The relationship between lipofuscin pigment and ageing in the human nervous system. J Neurol Sci (1978) 1.16
The transcriptional factor LBP-1c/CP2/LSF gene on chromosome 12 is a genetic determinant of Alzheimer's disease. Hum Mol Genet (2000) 1.16
A comparison of changes in the nucleus basalis and locus caeruleus in Alzheimer's disease. J Neurol Neurosurg Psychiatry (1984) 1.15
A pathological study of the association between Lewy body disease and Alzheimer's disease. J Neurol Neurosurg Psychiatry (1989) 1.15
The noradrenergic system in Alzheimer and multi-infarct dementias. J Neurol Neurosurg Psychiatry (1982) 1.15
Early senile plaques in Down's syndrome brains show a close relationship with cell bodies of neurons. Neuropathol Appl Neurobiol (1990) 1.15
The selective vulnerability of nerve cells in Huntington's disease. Neuropathol Appl Neurobiol (2001) 1.14
Contribution of APOE promoter polymorphisms to Alzheimer's disease risk. Neurology (2002) 1.14
Familial progressive aphasia: its relationship to other forms of lobar atrophy. J Neurol Neurosurg Psychiatry (1993) 1.12
Cytophotometric mapping of neuronal changes in senile dementia. J Neurol Neurosurg Psychiatry (1977) 1.11
Changes in nerve cells of the nucleus basalis of Meynert in Alzheimer's disease and their relationship to ageing and to the accumulation of lipofuscin pigment. Mech Ageing Dev (1984) 1.11
Pathological basis for neurotransmitter changes in Parkinson's disease. Neuropathol Appl Neurobiol (1983) 1.10
An integrative hypothesis concerning the pathogenesis and progression of Alzheimer's disease. Neurobiol Aging (1987) 1.10
Presynaptic serotonergic dysfunction in patients with Alzheimer's disease. J Neurochem (1987) 1.09
The topography of plaques and tangles in Down's syndrome patients of different ages. Neuropathol Appl Neurobiol (1987) 1.09
Neutralization of endotoxin in vitro and in vivo by a human lactoferrin-derived peptide. Infect Immun (1999) 1.09
Neuromelanin and RNA in cells of substantia nigra. J Neuropathol Exp Neurol (1977) 1.08
Consequences of Hox gene duplication in the vertebrates: an investigation of the zebrafish Hox paralogue group 1 genes. Development (2001) 1.07
The locus coeruleus and its possible role in ageing and degenerative disease of the human central nervous system. Mech Ageing Dev (1983) 1.06
A quantitative analysis of the incorporation of fibulin-1 into extracellular matrix indicates that fibronectin assembly is required. Matrix Biol (1995) 1.02
Loss of nerve cells from locus coeruleus in Alzheimer's disease is topographically arranged. Neurosci Lett (1986) 1.02
Neuropathological changes in Down's syndrome hippocampal formation. Effect of age and apolipoprotein E genotype. Arch Neurol (1995) 1.02
The topography of cell loss from locus caeruleus in Alzheimer's disease. J Neurol Sci (1986) 1.02
The effect of age and Alzheimer's disease on pyramidal neuron density in the individual fields of the hippocampal formation. Acta Neuropathol (1992) 1.00
Cognitive change in motor neurone disease/amyotrophic lateral sclerosis (MND/ALS). J Neurol Sci (2000) 1.00
Locus coeruleus cell loss in the aging human brain: a non-random process. J Comp Neurol (1995) 0.98
The topographic distribution of senile plaques and neurofibrillary tangles in the brains of non-demented persons of different ages. Neuropathol Appl Neurobiol (1987) 0.98
Alterations in protein synthetic capability of nerve cells in Alzheimer's disease. J Neurol Neurosurg Psychiatry (1981) 0.98
Possible role of neuromelanin in the pathogenesis of Parkinson's disease. Mech Ageing Dev (1983) 0.97
Quantification of modified amyloid beta peptides in Alzheimer disease and Down syndrome brains. J Neuropathol Exp Neurol (1998) 0.97
Neurotransmitter deficits in Alzheimer's disease and in other dementing disorders. Hum Neurobiol (1986) 0.97
Monoaminergic neurotransmitter systems in presenile Alzheimer's disease and in senile dementia of Alzheimer type. Clin Neuropathol (1985) 0.95
Colocalization of lysosomal hydrolase and beta-amyloid in diffuse plaques of the cerebellum and striatum in Alzheimer's disease and Down's syndrome. J Neuropathol Exp Neurol (1996) 0.95
The effects of ageing on the pigmented nerve cells of the human locus caeruleous and substantia nigra. Acta Neuropathol (1979) 0.95
Is the "preamyloid" of diffuse plaques in Alzheimer's disease really nonfibrillar? Am J Pathol (1993) 0.94
The DNA content of Purkinje cells in mammals. J Comp Neurol (1978) 0.94
Serglycin-binding proteins in activated macrophages and platelets. J Leukoc Biol (1996) 0.94
Phosphorylation of Tau proteins: a major event during the process of neurofibrillary degeneration. A comparative study between Alzheimer's disease and Down's syndrome. Brain Res (1990) 0.94
Monoclonal antibodies to purified cortical Lewy bodies recognize the mid-size neurofilament subunit. Ann Neurol (1997) 0.94
Incorporation of cellular and plasma fibronectins into smooth muscle cell extracellular matrix in vitro. Proc Natl Acad Sci U S A (1985) 0.93
Is the loss of cerebral cortical choline acetyl transferase activity in Alzheimer's disease due to degeneration of ascending cholinergic nerve cells. J Neurol Neurosurg Psychiatry (1982) 0.92
Collagenase production by early and late passage cultures of human fibroblasts. Exp Gerontol (1989) 0.92
Quantitative changes in cerebral cortical microvasculature in ageing and dementia. Neurobiol Aging (1987) 0.92
The substantia nigra and ventral tegmental area in Alzheimer's disease and Down's syndrome. J Neurol Neurosurg Psychiatry (1989) 0.92
The -48 C/T polymorphism in the presenilin 1 promoter is associated with an increased risk of developing Alzheimer's disease and an increased Abeta load in brain. J Med Genet (2001) 0.91
Serotonin nerve cells in Alzheimer's disease. J Neurol Neurosurg Psychiatry (1983) 0.91
Hypothalamus and dementia. Lancet (1981) 0.90
Overexpression of s100beta in Down's syndrome: correlation with patient age and with beta-amyloid deposition. Neuropathol Appl Neurobiol (1999) 0.90
The fine structure of the axonal torpedo in Purkinje cells of the human cerebellum. Neurol Res (1980) 0.89
Nerve cell protein metabolism and degenerative disease. Neuropathol Appl Neurobiol (1982) 0.89
Pathological evidence for neurotransmitter deficits in Down's syndrome of middle age. J Ment Defic Res (1985) 0.89
Variations in melanin content with age in the human substantia nigra. Biochem Exp Biol (1977) 0.89
Granulovacuolar degeneration in pyramidal cells of the hippocampus. Acta Neuropathol (1978) 0.89
Isolation and characterization of a Mr = 38,000 protein from differentiating smooth muscle cells. J Biol Chem (1985) 0.89
Normal frontal cortex histology and immunohistochemistry in patients with motor neuron disease. J Neurol Neurosurg Psychiatry (1995) 0.87
A quantitative assessment of somatostatin-like and neuropeptide Y-like immunostained cells in the frontal and temporal cortex of patients with Alzheimer's disease. J Neurol Sci (1990) 0.86
Allelic variations in apolipoprotein E and prion protein genotype related to plaque formation and age of onset in sporadic Creutzfeldt-Jakob disease. Neurosci Lett (1995) 0.86
The quantitative assessment of lipofuscin pigment, cytoplasmic RNA and nucleolar volume in senile dementia. Neuropathol Appl Neurobiol (1978) 0.86
Neurological disease and herpes simplex virus. An immunohistochemical study. Acta Neuropathol (1983) 0.86
Changes in Alzheimer's disease in the magnocellular neurones of the supraoptic and paraventricular nuclei of the hypothalamus and their relationship to the noradrenergic deficit. Clin Neuropathol (1985) 0.85
The site of the earliest lesions of Alzheimer's disease. N Engl J Med (1988) 0.85
Activated astrocytes display increased 5-HT2a receptor expression in pathological states. Exp Neurol (1999) 0.84
Neurofibrillary pathology and protein synthetic capability in nerve cells in Alzheimer's disease. Neuropathol Appl Neurobiol (1981) 0.84
Apolipoprotein E allelic frequencies in patients with lobar atrophy. Neurosci Lett (1995) 0.83